Quince Therapeutics, Inc. announced the successful settlement of the company?s outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. Effective immediately upon the $5.5 million payment, Quince settled outstanding EIB debt obligations of approximately $16.4 million as of March 27, 2026. As a direct result of this $5.5 million payment, all of the company?s obligations under both the settlement agreement and the underlying loan agreement have been fully satisfied and discharged.
The completion of the settlement resolves critical debt obligations and allows the company to advance its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Effective immediately upon the $5.5 million payment, Quince settled outstanding EIB debt obligations of approximately $16.4 million as of March 27, 2026. As a direct result of this $5.5 million payment, all of the company?s obligations under both the settlement agreement and the underlying loan agreement have been fully satisfied and discharged.
